NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on advancing surgical care for neurological disorders, announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference, scheduled for June 17-18, 2026. President and CEO Dave Rosa will attend the conference in Las Vegas, Nevada, where he is set to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time.
During the presentation, which will be held in TRACK 6 - Raphael 3, Rosa will provide commercialization updates and discuss anticipated milestones for the OneRF platform. The OneRF system is designed for the treatment of brain disorders, pain management, and advanced drug delivery, representing a significant step forward in minimally invasive neurological therapies. The company's technology portfolio includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, the OneRF Ablation System for the brain, and the OneRF Trigeminal Nerve Ablation System.
In addition to the live presentation, Rosa participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference. The interview can be viewed here. The conference aims to connect micro-cap companies with investors, and NeuroOne's participation underscores its commitment to expanding awareness of its innovative technologies among the investment community.
The implications of this announcement are significant for the medical technology industry and patients suffering from neurological disorders. NeuroOne's electrode technology platform offers the potential to reduce the number of hospitalizations and surgical procedures, lower healthcare costs, and improve patient outcomes by combining diagnostic and therapeutic functions in a single device. The OneRF platform, in particular, could transform the treatment of chronic pain and brain disorders by providing a minimally invasive alternative to traditional surgery.
NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs, indicating a broad pipeline of future offerings. The company's focus on high-definition, high-precision electrodes addresses a critical need in neurosurgery, where accuracy is paramount. By presenting at the Planet MicroCap Conference, NeuroOne aims to attract institutional investment to support its ongoing R&D efforts and commercial expansion.
For more information about the conference or to schedule a meeting with management, interested parties can contact the conference representative or email NMTC@mzgroup.us. Further details about NeuroOne and its technologies are available at nmtc1.com.
